Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
It becomes a much weaker tool for patients with a BMI over 35 or obesity-related conditions like Type 2 diabetes, hypertension, or sleep apnea
Purpose-built for physicians Most adults with overweight or obesity discontinue GLP-1 therapy within 2 years Key takeaways: Of adults prescribed a GLP-1 receptor agonist, 53.6% ended therapy at 1 year and 72.2% stopped therapy at 2 years
Baseline characteristics of case and control subjects after matching Values are presented as meanstandard deviation or number (%)
Thank you again!" Verified Customer Individual results may vary
As of March 2024 , Wegovys labeling was updated and no longer includes specific BMI criteria
US$ 26.68
US$ 25.63
US$ 29.78
